Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients |
| |
Authors: | Stefan Hettwer Pius Dahinden Stefan Kucsera Carlo Farina Shaheen Ahmed Ruggero Fariello Michael Drey Cornel Christian Sieber Jan Willem Vrijbloed |
| |
Affiliation: | 1. Neurotune AG, Wagistrasse 27a, Schlieren, Switzerland;2. Geriatrie der Universität, Erlangen-Nürnberg am Klinikum Nürnberg, Medizinische Klinik 2, Prof.-Ernst-Nathan Strasse 1, 90419 Nürnberg, Germany |
| |
Abstract: | Sarcopenia is a recently defined medical condition described as age-associated loss of skeletal muscle mass and function. Recently, a transgenic mouse model was described linking dispersal of the neuromuscular junction caused by elevated agrin degradation to the rapid onset of sarcopenia. These mice show a significant elevation of serum levels of a C-terminal agrin fragment (CAF) compared to wild-type littermates. A series of experiments was designed to ascertain the significance of elevated agrin degradation in the development of human sarcopenia. A quantitative Western blot method was devised to detect CAF in sera of humans. A first trial on consenting blood donors (n = 169; age 19–74 years) detected CAF in the limited range of 2.76 ± 0.95 ng/ml. In sarcopenia patients (diagnosed according to clinical and instrumental standards) mean CAF levels were significantly elevated (p = 9.8E10-9; n = 73; age 65–87 years) compared to aged matched controls. Of all sarcopenia patients, 40% had elevated, non-overlapping CAF levels compared to controls. Evidence is presented for a pathogenic role of the agrin/neurotrypsin system in a substantial subset of sarcopenia patients. These patients are characterized by elevated CAF blood levels compared to aged-matched healthy volunteers suggesting the identification of an agrin-dependent form of sarcopenia. Elevated CAF levels in a large subpopulation of sarcopenic patients suggest the existence of a specific form of sarcopenia for which CAF could become a biomarker and a new target for therapeutic interventions. The feasibility of this approach was demonstrated by the development of a small molecule capable of inhibiting neurotrypsin in vitro and in vivo. |
| |
Keywords: | Frailty Neurotrypsin Biomarker Mouse model Neuromuscular junction |
本文献已被 ScienceDirect 等数据库收录! |
|